Medtronic’s Valiant Navion Thoracic Stent Graft Cleared in EU

Medtronic won European CE Mark approval to introduce its Valiant Navion thoracic stent graft for treating lesions within the descending thoracic aorta such as thoracic aortic aneurysms (TAA), blunt traumatic aortic injuries (BTAI), and penetrating atherosclerotic ulcers (PAU). The system received FDA approval in October of this year. The Valia (Read more...)

Point-of-Care BRCA1 Mutation Testing in 20 Minutes

BReast CAncer gene one (BRCA1) is one of the best-known genes linked to breast cancer risk. Unfortunately, the technology to spot the gene requires a lab and expertise at interpretation. Researchers at Louisiana State University have now developed a smartphone-based system called FLuoroZen that can test for the cancer-related BRCA1 mutation at the (Read more...)

Quarterly loss decreases for ProQR

ProQR Therapeutics reported a net loss of 6 million euros, or 0.18 euros per share, in the third quarter of 2018 compared with a net loss of 10.5 million euros, or 0.42 euros per share, in the previous year’s third quarter.Research and development cost…